BagotKS, MilinR, KaminerY. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abus, 2015; 36(4):524–533; doi: 10.1080/08897077.2014.995332
2.
BlaineSK, MilivojevicV, FoxH, et al.Alcohol effects on stress pathways. Can J Psychiatry, 2016; 61(3):145–153; doi: 10.1177/0706743716632512
3.
BrosnanRJ, FukushimaFB, PhamTL. Anesthetic synergy between two n-alkanes. Vet Anaesth Analg, 2017; 44(3):577–588; doi: 10.1016/j.vaa.2016.07.003
4.
DeanAJ, SaundersJB, JonesRT, et al.Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci, 2006; 31(1):38–45.
5.
ElchaarGM, MaischNM, AugustoLMG, et al.Pediatrics efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother, 2006; 40(6):1086–1095; doi: 10.1345/aph.1G499
6.
FeeneyGFX, ConnorJP, YoungRM, et al.Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centres’ experience with pharmacotherapy. Alcohol, 2006; 41(3):321–327; doi: 10.1093/alcalc/agl007
7.
GoedersNE. Chapter 2—The hypothalamic-pituitary-adrenal axis and addiction. In: Stress and Addiction. (al’AbsiM. Ed.) Academic Press: Burlington; 2007; pp. 21–40; doi: 10.1016/B978-012370632-4/50005-X
8.
GriffinKW, BotvinGJ. Evidence-based interventions for preventing substance use disorders in adolescents. Child Adolesc Psychiatr Clin N Am, 2010; 19(3):505–526; doi: 10.1016/j.chc.2010.03.005
9.
HalladayJ, WoockR, El-KhechenH, et al.Patterns of substance use among adolescents: A systematic review. Drug Alcohol Depend, 2020; 216:108222; doi: 10.1016/j.drugalcdep.2020.108222
10.
HaneyM, ValléeM, FabreS, et al.Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: Phase 1 and phase 2a randomized trials. Nat Med, 2023; 29(6):1487–1499; doi: 10.1038/s41591-023-02381-w
11.
KingAC, SchlugerJ, GunduzM, et al.Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: Preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology, 2002; 26(6):778–788; doi: 10.1016/S0893-133X(01)00416-X
LochmanJE, van den SteenhovenA. Family-based approaches to substance abuse prevention. J Prim Prev, 2002; 23(1):49–114; doi: 10.1023/A:1016591216363
14.
MoleroY, ZetterqvistJ, BinswangerIA, et al.Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime. Am J Psychiatry, 2018; 175(10):970–978; doi: 10.1176/appi.ajp.2018.17101112
15.
MoorI, WinterK, RathmannK, et al.Alcohol, tobacco and cannabis use in adolescence—cross-sectional results of the 2017/18 HBSC study. J Health Monit, 2020; 5(3):69–87; doi: 10.2564/6/6903
16.
NaPJ, ScodesJ, FishmanM, et al.Co-occurring depression and suicidal ideation in opioid use disorder: Prevalence and response during treatment with buprenorphine-naloxone and injection naltrexone. J Clin Psychiatry, 2022; 83(3):40618; doi: 10.4088/JCP.21m14140
17.
NewcombMD, LockeT. Health, social, and psychological consequences of drug use and abuse. In: Epidemiology of Drug Abuse. (SlobodaZ. Ed.) Springer US: Boston, MA; 2005; pp. 45–59; doi: 10.1007/0-387-24416-6_4
StancilSL, Abdel-RahmanS, WagnerJ. Developmental considerations for the use of naltrexone in children and adolescents. J Pediatr Pharmacol Ther, 2021; 26(7):675–695; doi: 10.5863/1551-6776-26.7.675
24.
TomekSE, LaCrosseAL, NemirovskyNE, et al.NMDA receptor modulators in the treatment of drug addiction. Pharmaceuticals (Basel), 2013; 6(2):251–268; doi: 10.3390/ph6020251
25.
Treatment C for SA. Chapter 4—Oral Naltrexone. In: Incorporating Alcohol Pharmacotherapies Into Medical Practice. Substance Abuse and Mental Health Services Administration (US); 2009.
26.
TrivediM, WalkerR, LingW, et al.Bupropion and Naltrexone in Methamphetamine Use Disorder | NEJM. 2021. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2020214 [Last accessed: December27, 2023].
